araag2/HINT huggingface dataset:
Clinical trial NCT00555100 (phase 1, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: lenalidomide, dexamethasone
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with previously treated multiple myeloma

          -  Measurable levels of m-protein in serum >= 0.5 g/dL [5g/L]) or urine (>= 0.2 g
             excreted in a 24-hour collection sample)

          -  ECOG performance status of 0 - 2

          -  Willing to follow pregnancy precautions

        Exclusion Criteria:

          -  Patients with acute an myocardial infarction (MI) within the past 6 months, or
             patients with a history of deep vein thrombosis (DVT) or pulmonary embolism (PE)
             within the past 3 years

          -  Patients with tuberculous diseases, herpes simplex keratitis, systemic mycosis or
             other active infectious diseases

          -  Patients with non-controlled diabetes, hypertension, digestive ulcer or glaucoma

          -  Patients with posterior subcapsular cataracts

          -  Patients with mental illness

          -  Patients with past histories or complications which make the Investigator or other
             staff member deem them inappropriate for this study

          -  Pregnant or lactating females

          -  Grade 2 or worse neuropathy

          -  Any of the following laboratory abnormalities:

        Absolute neutrophil count (ANC) < 1,000cells/mL Platelet count < 75,000/mL Serum creatinine
        > 2.5 mg/dL Serum SGOT/AST or SGPT/ALT > 3.0 x upper limit of normal (ULN)

          -  Prior history of malignancies, other than multiple myeloma, unless the subject has
             been free of the disease for >= 3 years. - Patients who received radiation therapy
             within 14 days of the start of study drug

          -  Patients with scars from a recent viscus operation

          -  Patients with history of a desquamating (blistering) rash while taking thalidomide

          -  Patients with prior use of lenalidomide

          -  Patients with known HIV positivity.

          -  Patients who used cytotoxic chemotherapeutic agents, immunomodulating agents, or other
             experimental agents (agents that are not commercially available) intended for the
             treatment of MM within 28 days of the start of lenalidomide therapy.

          -  Patients with known history of hypersensitivity to dexamethasone.
Clinical trial NCT00038480 (phase 1, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: lopinavir/ritonavir
SMILES: OC(=O)[C@@H]1CCCN1
Eligibility criteria:

        Inclusion Criteria

          -  HIV infected

          -  Viral load greater than 10,000 copies/ml within 30 days prior to study entry

          -  Weigh more than 5.5 lbs at the time of enrollment

          -  Agree to take 2 nucleoside reverse transcriptase inhibitors (NRTIs) in addition to
             LPV/RTV

          -  Have consent of parent or guardian willing to provide signed informed consent and to
             have the infant followed at a PACTG site

        Exclusion Criteria

          -  Currently taking a nonnucleoside reverse transcriptase inhibitor or protease inhibitor
             (PI) while on study

          -  Previously used LPV/RTV. Patients who were treated previously with other PIs are not
             excluded. Prior or concurrent maternal treatment with LPV/RTV is not excluded.

          -  For patients less than 6 weeks old at time of enrollment, less than 34 weeks gestation
             at delivery OR for patients 6 or more weeks old at time of enrollment, less than 32
             weeks gestation at delivery

          -  Any laboratory toxicity of Grade 3 or greater. Hyperlipasemia of Grade 2 or higher is
             also excluded.

          -  Newly diagnosed acute opportunistic or serious bacterial infection requiring therapy
             at the time of enrollment

          -  Chemotherapy for active cancer

          -  Certain medications

          -  Any other clinically significant conditions, other than HIV infection, that would
             interfere with the study
Clinical trial NCT01337765 (phase 1, status: completed)
Conditions: unspecified adult solid tumor, protocol specific, solid tumor
ICD codes: H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509
Drugs: bez235 + mek162
SMILES: CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C=C12)C(=O)NOCCO
Eligibility criteria:

        Inclusion Criteria:

          -  histologically/cytologically confirmed, advanced non resectable solid tumors

          -  Measurable or non-measurable, but evaluable disease as determined by RECIST 1.0

        Exclusion Criteria:

          -  Patients with primary CNS tumor or CNS tumor involvement

          -  Diabetes mellitus - Unacceptable ocular/retinal conditions

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01018745 (phase 1, status: completed)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bms-907351 (xl184)
SMILES: COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced or metastatic solid tumors for whom the standard of care is ineffective or
             inappropriate

          -  Life expectancy of at least 3 months

          -  Eastern Cooperative Oncology Group performance 0-2

        Exclusion Criteria:

          -  Subject has uncontrolled intercurrent illness
Clinical trial NCT00426530 (phase 1, status: completed)
Conditions: breast neoplasms, neoplasm metastasis
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: everolimus (rad001)
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion criteria:

          -  Female or male patients ≥18 years with WHO performance status ≤ 1

          -  HER-2 overexpressing metastatic breast cancer cells confirmed by histology

          -  Progressive disease on prior trastuzumab alone/or in combination with other anticancer
             agents, or relapsed any time after completion of this therapy

          -  Patients neurologically stable with adequate bone marrow, liver and renal function

        Exclusion criteria:

          -  Patients receiving endocrine therapy for breast cancer ≤ 2 weeks prior to study
             treatment start

          -  Patients currently receiving chemotherapy, immunotherapy or radiotherapy or who have
             received these ≤ 4 weeks prior to study treatment start or patients who have received
             lapatinib ≤ 2 weeks prior to study treatment start

          -  Patients who have previously received vinorelbine or mTOR inhibitors

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00304005 (phase 1/phase 2, status: completed)
Conditions: leukemia, lymphoma
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: laromustine
SMILES: CNC(=O)N(N(CCCl)S(C)(=O)=O)S(C)(=O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following hematologic malignancies:

               -  Fludarabine refractory or relapsed chronic lymphocytic leukemia (CLL)

                    -  CLL in transformation allowed

               -  Richter syndrome

               -  Other refractory lymphoproliferative diseases

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Creatinine ≤ 2.0 mg/dL

               -  Renal dysfunction due to organ infiltration by disease allowed

          -  AST and ALT ≤ 3 times upper limit of normal (ULN) (unless due to organ infiltration by
             disease)

          -  Bilirubin ≤ 1.5 times ULN (unless due to Gilbert's syndrome)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No uncontrolled infection

          -  No symptomatic coronary artery disease

          -  No arrhythmia not controlled by medication

          -  No uncontrolled, symptomatic congestive heart failure

          -  No myocardial infarction within the past 3 months

          -  No other uncontrolled illness

          -  No psychiatric illness or social situation that would preclude study compliance

        PRIOR CONCURRENT THERAPY:

          -  At least 2 weeks since prior cytotoxic therapy except in patients with rapidly
             progressing disease

          -  No other concurrent standard or investigational treatment for this cancer

          -  No other concurrent cytotoxic investigational drugs

          -  No concurrent disulfiram
Clinical trial NCT00442611 (phase 1/phase 2, status: completed)
Conditions: scleroderma, diffuse, scleroderma, systemic
ICD codes: L94.1, L94.0
Drugs: abatacept, placebo
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of diffuse systemic sclerosis

          -  age 18 years or older

          -  Adequate renal, pulmonary, and cardiovascular function

          -  Willingness to use effective contraception for the duration of the study if subject is
             of childbearing potential&#xA;

        Exclusion Criteria:

          -  Other connective tissues diseases or overlap syndromes including MCTD, SLE, RA,
             eosinophilic fasciitis, and limited systemic sclerosis or morphea

          -  Use of disease modifying agents including methotrexate, cyclosporine,azathioprine,
             mycophenolate mofetil, minocycline, doxycycline, minocycline, thalidomide,
             penicillamine, tamoxifen, colchicine, or investigational agent within 90 days of
             screening visit

          -  HIV, Hepatitis B or Hepatitis C infection

          -  use of prednisone greater than 10mg daily for 28 days prior to screening visit

          -  women who are breastfeeding or pregnant
Clinical trial NCT01565928 (phase 1, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: mdv3100
SMILES: CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to provide informed consent;

          -  Men, 18 years of age or older;

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate;

          -  Ongoing androgen deprivation therapy

        Exclusion Criteria:

          -  Severe concurrent disease;

          -  Known or suspected brain metastasis;

          -  History of another malignancy within the previous 5 years;

          -  Prior treatment with docetaxel-based chemotherapy
Clinical trial NCT01464931 (phase 1, status: completed)
Conditions: renal impairment
ICD codes: M10.38, M10.30, M10.311, M10.312, M10.319, M10.321, M10.322
Drugs: denosumab
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects at least 18 years old with severe CKD (defined as creatinine clearance < 30
             mL/min at both screening assessments) and CKD requiring hemodialysis

          -  Additional inclusion criteria apply

        Exclusion Criteria:

          -  Subjects must have calcium, phosphate, and magnesium levels appropriate for their
             condition and must not have other uncontrolled co-morbidities.

          -  Additional exclusion criteria apply
Clinical trial NCT00417885 (phase 1/phase 2, status: terminated)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: exemestane, sunitinib malate
SMILES: CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
Reason stopped: 
    see detailed description for termination reason
  
Eligibility criteria:

        Inclusion Criteria:

          -  At least 18 years of age

          -  Estrogen and/or progesterone receptor positive adenocarcinoma of the breast with
             evidence of 1) unresectable 2)locally recurrent, or 3) metastatic disease

          -  Postmenopausal

          -  ECOG [Eastern Cooperative Oncology Group] </=1

          -  Evaluable(e.g bone only disease allowed) and Measurable disease [RECIST (Response
             Evaluation Criterion in Solid Tumors)]

        Exclusion Criteria:

          -  HER2 [Human Epidermal Growth factor Receptor 2] positive disease not previously
             treated with herceptin

          -  Any prior anti-angiogenic therapy, endocrine or cytotoxic anti-cancer therapy in the
             metastatic disease setting

          -  Radiation therapy within 2 weeks of first study treatment
Clinical trial NCT01759056 (phase 1, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: avx 470, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women aged 18 75, inclusive

          -  Established diagnosis of ulcerative colitis involving the sigmoid colon or proximal
             segments of bowel

          -  Total Mayo score between 5-12, inclusive, with endoscopic subscore of the Mayo score ≥
             2 and > 15 cm of involvement beyond the anal verge

        Exclusion Criteria:

          -  Women with a positive pregnancy test, who are breastfeeding, or who intend to become
             pregnant during the course of the study

          -  Diagnosis of Crohn's disease, microscopic colitis or indeterminate colitis

          -  Presence of ileostomy or colostomy, or history of prior colon resection

          -  Patients with planned hospitalization or surgery during the course of the study

          -  Known allergy to milk proteins, red meat or cornstarch

          -  Stools positive for enteric infection, including parasitic, or C. difficile toxin
             within 28 days of screening

          -  Documented presence of Hetatitis B (HBsAg), Hepatitis C (HCV), or HIV

          -  Presence of dysplasia of any grade on colonoscopic biopsies

          -  Treatment for cancer (excluding non-melanomatous cancer of the skin or cervical
             carcinoma in situ) or lymphoproliferative disorder (including lymphoma) within 5 years

          -  History of tuberculosis (TB) or Listeria infection, or known exposure to another
             person with active TB disease within 12 weeks of screening; or history of past or
             current infection with different opportunistic infections

          -  History of TNF inhibitor (infliximab, adalimumab or certolizumab pegol) use with
             primary treatment failure. Secondary treatment failures due to intolerance, allergic
             reaction, or loss of response will not constitute a basis for exclusion. Oral
             immunosuppressives, mesalamine, and corticosteroids (up to 20mg of prednisone per day)
             will be permitted so long as these medications are stable for defined periods of time
             before study participation commences.
Clinical trial NCT00287859 (phase 1, status: terminated)
Conditions: fallopian tube cancer, ovarian cancer, peritoneal cavity cancer
ICD codes: C57.00, C57.01, C57.02, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C30.0, Z12.81, D14.0, C14.8, D37.09, Z86.003, Z85.818
Drugs: topotecan hydrochloride
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Reason stopped: 
    withdrawn due to low accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histological diagnosis of ovarian epithelial, fallopian tube, or primary peritoneal
             cavity cancer

               -  Progressive or recurrent disease

          -  Received ≥ 1 prior course of chemotherapy

          -  Measurable or evaluable disease OR disease assessable by CA 125, defined as CA 125 >
             normal that has increased over 2 readings > 14 days apart

          -  Karnofsky performance status 10-50%

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Creatinine ≤ 1.5 mg/dL

          -  Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)

          -  Total bilirubin ≤ 1.5 times ULN

          -  SGOT ≤ 3 times ULN

          -  Life expectancy ≥ 12 weeks

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use accepted and effective non-hormonal contraception

        Exclusion Criteria:

          -  Other neoplasm within the past 5 years except for nonmetastatic, nonmelanoma skin
             cancers, carcinoma in situ of the cervix, or cancer cured by surgery or chemotherapy

          -  Septicemia, severe infection, or acute hepatitis

          -  Severe gastrointestinal bleeding, defined as requiring a blood transfusion or
             hospitalization
Clinical trial NCT01606371 (phase 1, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, ly2409021
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=CC(O[C@@H](CCC(F)(F)F)C2=CC=C(C=C2)C(=O)NCCC(O)=O)=CC(C)=C1C1=CC=C(C=C1)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

        For all participants:

          -  Must be either a male, or a female who cannot become pregnant, who is either healthy
             or have type 2 diabetes mellitus (T2DM) but not taking medication for diabetes

          -  Have an hemoglobin A1c (HbA1c) value of less than or equal to 10% at screening

          -  Have blood and urine laboratory test results that are acceptable for the study

        For healthy participants:

          -  Have a screening body mass index (BMI) of 18.5 to 29.9 kg/m^2 inclusive

          -  Have a fasting blood glucose between 3.0-5.2 millimoles/liter (mmol/L) at screening

          -  Have plasma glucose, two hours after ingesting an oral 75 g glucose load, less than
             7.8 mmol/L

        For participants with type 2 diabetes mellitus (T2DM):

          -  Have a screening body mass index (BMI) of 18.5 to 35 kg/m^2 inclusive

          -  Must weigh 45 kg or more at screening

          -  Have a fasting blood glucose less than 11.1 mmol/L at screening

          -  Have plasma glucose, two hours after ingesting an oral 75 g glucose load, greater than
             or equal to 11.1 mmol/L

        Exclusion Criteria:

        For all participants:

          -  Have participated in a study with a new drug in the last 30 days

          -  Have a history of significant heart, lung, liver, kidney, stomach or brain disease, or
             have any medical problems which may cause an increased risk during the study

          -  Have hypertension requiring more than single-agent therapy, or blood pressure greater
             than 140/90 millimeters of mercury (mmHg) on monotherapy

          -  Are allergic to LY2409021 or similar drugs

          -  Have a regular alcohol intake greater than 21 units/week (male), or 14 units/week
             (female), or are unwilling to stop alcohol as required by the study restrictions (1
             unit = 360 mL of beer, or 150 mL of wine, or 45 mL of spirits)

          -  Intend to use other over-the-counter or prescribed medicines during 7 or 14 days
             respectively before the study, or during the study. Medicines for high cholesterol and
             high blood pressure are allowed if you have diabetes.

          -  Have a significant blood disorder and/or donated blood (450 ml or more) in the last 3
             months

        For participants with T2DM:

          -  Have signs of having serious problems with diabetes (For example, severe eye problems,
             poorly healing skin)

          -  Have a history of being in a coma due to low blood sugar
Clinical trial NCT00398567 (phase 1/phase 2, status: completed)
Conditions: advanced breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: hki-272, trastuzumab
SMILES: CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C(C=NC2=C1)C#N, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologic diagnosis of breast cancer with current stage IIIB, IIIC or IV not curable
             by available therapy

          -  Progression following at least one Herceptin-containing cytotoxic chemotherapy regimen
             (neoadjuvant, adjuvant, or metastatic setting)

          -  HER2 positive breast cancer

          -  At least one measurable target lesion

          -  Adequate performance status

          -  Adequate cardiac, kidney, and liver function

          -  Adequate blood counts

          -  Willingness of all subjects who are not surgically sterile or post menopausal to use
             acceptable methods of birth control

        Exclusion Criteria:

          -  More than 3 prior cytotoxic chemotherapy regimens for locally advanced or metastatic
             disease

          -  Major surgery, chemotherapy, radiotherapy, investigational agents, Herceptin or other
             cancer therapy within 2 weeks of treatment day 1

          -  Prior treatment with anthracyclines with cumulative dose of >400 mg/m^2

          -  Extensive visceral disease

          -  Active central nervous system metastases

          -  Pregnant or breast feeding women

          -  Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major
             symptom

          -  Prior exposure to HKI-272 or other HER2 targeted agents (except Herceptin and Tykerb)

          -  Significant cardiac disease or dysfunction

          -  History of life-threatening hypersensitivity to Herceptin

          -  Inability or unwillingness to swallow HKI-272 capsules

          -  Any other cancer within 5 years with the exception of contralateral breast cancer,
             adequately treated cervical carcinoma in situ, or adequately treated basal or squamous
             cell carcinoma of the skin